Predictive Factors for Response and Outcome in Patients (pts) Treated with Second Generation Tyrosine Kinase Inhibitors (2-TKI) for Chronic Myeloid Leukemia in Chronic Phase (CML-CP) Post Imatinib Failure

被引：0
|
作者：
Jabbour, Elias [1 ]
Kantarjian, Hagop [1 ]
O'Brien, Susan [1 ]
Shan, Jenny [1 ]
Garcia-Manero, Guillermo
Wierda, William [1 ]
Ravandi, Farhad [1 ]
Borthakur, Gautam [1 ]
Rios, Mary Beth [1 ]
Cortes, Jorge [1 ]
机构：
[1] Univ Texas MD Anderson Canc Ctr, Leukemia Dept, Houston, TX 77030 USA
来源：
BLOOD | 2009年 / 114卷 / 22期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：210 / 211
页数：2
相关论文
共 50 条
  • [1] Predictive factors for outcome and response in patients treated with second-generation tyrosine kinase inhibitors for chronic myeloid leukemia in chronic phase after imatinib failure
    Jabbour, Elias
    Kantarjian, Hagop
    O'Brien, Susan
    Shan, Jenny
    Garcia-Manero, Guillermo
    Wierda, William
    Ravandi, Farhad
    Borthakur, Gautam
    Rios, Mary Beth
    Cortes, Jorge
    BLOOD, 2011, 117 (06) : 1822 - 1827
  • [2] Prognostic significance of prior best response to imatinib in patients (pts) with chronic myeloid leukemia (CML) in chronic phase (CP)Treated with second generation tyrosine kinase inhibitors (TKIs)
    Jabbour, Elias
    Kantarjian, Hagop
    Shan, Jenny
    O'Brien, Susan
    Wierda, William
    Ravandi, Farhad
    Borthakur, Gautant
    Komblau, Steven
    Walker, Brenda K.
    Rios, Mary Beth
    Cortes, Jorge
    BLOOD, 2007, 110 (11) : 577A - 577A
  • [3] Incidence of Secondary Malignancies in Patients with Chronic Myeloid Leukemia in Chronic Phase (CML-CP) in the Era of Tyrosine Kinase Inhibitors (TKI)
    Sasaki, Koji
    Kantarjian, Hagop M.
    O'Brien, Susan M.
    Ravandi, Farhad
    Konopleva, Marina
    Borthakur, Gautam
    Garcia-Manero, Guillermo
    Wierda, William G.
    Daver, Naval
    Ferrajoli, Alessandra
    Takahashi, Koichi
    Jain, Preetesh
    Rios, Mary B.
    Pierce, Sherry
    Jabbour, Elias J.
    Cortes, Jorge E.
    BLOOD, 2017, 130
  • [4] Outcome After Failure to Second Generation Thyrosine Kinase Inhibitors(TKI) Treatment as Frontline Therapy for Patients with Chronic Myeloid Leukemia (CML) In Chronic Phase(CP)
    Eghtedar, Alireza
    Kantarjian, Hagop
    Jabbour, Elias
    o'Brien, Susan
    Quintas-Cardama, Alfonso
    Burton, Elizabeth
    Garcia-Manero, Guillermo
    Verstovsek, Srdan
    Konopleva, Marina
    Cortes, Jorge E.
    BLOOD, 2010, 116 (21) : 1411 - 1412
  • [5] Dynamics of Response and Response Factors in Patients (Pts) with Chronic Myeloid Leukemia in Chronic Phase (CML-CP) after ≥2 Prior Tyrosine Kinase Inhibitors (TKIs) in the Phase 3 Ascembl Study
    Hughes, Timothy
    Rea, Delphine
    Boquimpani, Carla
    Minami, Yosuke
    Mauro, Michael
    Cortes, Jorge E.
    Apperley, Jane F.
    Gutierrez, Valentin Garcia
    Kapoor, Shruti
    Allepuz, Alex
    Quenet, Sarah
    Zhang, Yifan
    Hochhaus, Andreas
    BLOOD, 2022, 140 : 6757 - 6759
  • [6] Outcome after Discontinuation of Second Generation Tyrosine Kinase Inhibitors (TKIs) Used As Frontline Therapy for Patients (pts) with Chronic Phase (CP) Chronic Myeloid Leukemia (CML)
    Abdelall, Waleed
    Kantarjian, Hagop M.
    Devendra, K. C.
    Akosile, Mary
    Borthakur, Gautam
    Verstovsek, Srdan
    Daver, Naval
    Pemmaraju, Naveen
    Naqvi, Kiran
    Garcia-Manero, Guillermo
    Thompson, Philip A.
    Ferrajoli, Alessandra
    Ravandi, Farhad
    Konopleva, Marina
    DiNardo, Courtney D.
    Jabbour, Elias J.
    Cortes, Jorge E.
    BLOOD, 2017, 130
  • [7] Memory Impairment in Chronic phase (CP) Chronic Myeloid Leukemia (CML) Patients (pts) Treated with Dasatinib Tyrosine Kinase Inhibitor (TKI) Therapy
    Pemmaraju, Naveen
    Kantarjian, Hagop M.
    Tanaka, Maria F.
    O'Brien, Susan
    Jabbour, Elias
    Quintas-Cardama, Alfonso
    Borthakur, Gautam
    Ravandi, Farhad
    Verstovsek, Srdan
    Burton, Elizabeth
    Walker, Brenda
    Cortes, Jorge E.
    BLOOD, 2011, 118 (21) : 1610 - 1611
  • [8] EUTOS Score Is Not Predictive for Survival and Outcome in Patients (pts) with Chronic Myeloid Leukemia in Early Chronic Phase (CML-CP) Treated with Tyrosine Kinase Inhibitors (TKIs) At MD Anderson Cancer Center (MDACC)
    Nazha, Aziz
    Jabbour, Elias
    Cortes, Jorge E.
    O'Brien, Susan
    Shan, Jenny
    Garcia-Manero, Guillermo
    Quintas-Cardama, Alfonso
    Kantarjian, Hagop M.
    BLOOD, 2011, 118 (21) : 1609 - 1609
  • [9] Survival outcomes for patients (Pts) with chronic myeloid leukemia (CML) with clonal evolution (CE) treated with 2nd generation tyrosine kinase inhibitors (TKI) after imatinib failure
    Verma, Dushyant
    Kantarjian, Hagop
    Estrov, Zeev
    Garcia-Mancro, Guillermo
    Koller, Charles
    Borthakur, Gautam
    Cortes, Jorge
    BLOOD, 2007, 110 (11) : 866A - 867A
  • [10] Effectiveness of Tyrosine Kinase Inhibitors in Patients with Chronic Myeloid Leukemia in Chronic Phase (CML-CP) after Two or More Prior Tyrosine Kinase Inhibitors
    Dahlen, Torsten
    Kockerols, Camille C. B.
    Ferreira, Germano
    Westerweel, Peter E.
    Mayer, Jiri
    Allepuz, Alex
    Wormser, David
    Yau, Lillian
    Zackova, Daniela
    BLOOD, 2022, 140 : 3889 - 3890
12345